ClinicalTrials.gg
CompletedNCT00887861Updated Mar 21, 2017

Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery

A Phase 2 interventional study of Investigational new drug, company code: BGG492 and Placebo in Seizures and Epilepsy, sponsored by Novartis. Completed at 6 sites in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-03-21.

Sponsored by Novartis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Seizures by Novartis — none open to participants now, 1 under way, 1 of them phase 3. Seizures · Novartis.

Enrollment
9th of 11
37 · median 94
Started
2009
with 2 others
Phase 2
Only one
of the 11
Registered
7th of 11
by date

Among the 11 studies in Seizures by Novartis, this one is the 9th largest by enrollment, is one of 3 that started in 2009, is the only one in phase 2, and was the 7th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

None of the 11 studies in Seizures by Novartis is open now. The open studies under Seizures, anywhere →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Seizures by Novartis as a file.
02

Study summary

This study will asses the safety and efficacy of BGG492 in reducing the seizure rate in therapy-refractory partial seizures.

03

Conditions studied

  • Seizures
  • Epilepsy

Keywords

  • epilepsy
  • seizure
  • monotherapy trials
  • partial seizure
  • Partial seizures and undergoing evaluation for epilepsy surgery
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A diagnosis of partial seizures (with or without secondary generalization) and undergoing an evaluation for epilepsy surgery, based on the classification of the International League Against Epilepsy (ILAE), as modified in 1981.
  2. Absence of evolving space-occupying lesions or progressive neurological diseases.
  3. Have normal vital signs (systolic and diastolic blood pressure and pulse rate)
  4. All female subjects must have negative pregnancy test results
  5. Subjects must weigh at least 50 kg to participate in this study and must have a (BMI) within the range of 18 to 35.

Exclusion criteria

Exclusion Criteria:

  1. A history of frequent and/or severe status epilepticus (i.e. requiring intensive care unit treatment).
  2. Current treatment with phenobarbital, primidone or zonisamide (these drugs would have to be completely washed out before study start)
  3. Having discontinued chronic benzodiazepine and barbiturate therapy within 30 days prior to the study start
  4. Having electrodes implanted in the brain.
  5. Having evidence on physical examination, or a history of any medically significant thyroid, cardiac, respiratory, hepatic, gastrointestinal, renal, hematologic, oncologic, psychiatric or progressive neurological disorder, requiring current medical intervention/therapy likely to have a significant impact on the outcome of this study.
  6. With any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs, e.g. GI surgery and/or pancreatic or liver disease
  7. Having a significant illness other than epilepsy within two (2) weeks prior to initial dosing.
  8. Having recent (within the last three (3) years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc).

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    BGG492

    Drug: Investigational new drug, company code: BGG492

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Measure: An efficacy of investigation drug versus Placebo in reducing the seizure rate when administered orally for up to 7days as monotherapy in patients with refractory partial seizures who are undergoing an inpatient evaluation for epilepsy

    Time frame: 7 days

Secondary outcomes

  1. Measure:An efficacy of investing. drug vs. Pcb in reducing the seizure rate when administered orally for up to 9days (during titration monotherapy)in pts. with refractory partial seizures who are undergoing an inpatient evaluation for epilepsy surgery.

    Time frame: 9 days

  2. Measure: To evaluate the safety and tolerability of investigational drug repeated dose over 9 days in patients with refractory partial seizures

    Time frame: 9 days

  3. Measure: To determine the plasma levels of investigational drug in patients with refractory partial seizures.

    Time frame: 9 days

07

Study locations

6 sites
  • Novartis Investigator Site
    Berlin, Germany
  • Novartis Investigator Site
    Bielefeld, Germany
  • Novartis Investigator Site
    Bonn, Germany
  • Novartis Investigator Site
    Erlangen, Germany
  • Novartis Investigator Site
    Freiburg, Germany
  • Novartis Investigator Site
    Munich, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2009
First posted
Apr 24, 2009
Start
Mar 2009
Primary completionActual
Aug 2010
CompletionActual
Aug 2010
Last update
Mar 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00887861
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Apr 24, 2009
Start date
Mar 2009
Primary completion
Aug 2010
Completion
Aug 2010
Last update
Mar 21, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Drugs, Investigational · Selurampanel

Start the discussion